Hemispherx Biopharma, Inc. [NYSE:HEB]: Analyst Rating and Earnings

Equities traders frequently stay up to date regarding what leading market analysts think about a possible stock buy. As it relates to Hemispherx Biopharma, Inc. [HEB], the latest mean analyst recommendation that’s publicly available is from the fiscal three-month period ending in December. On average, stock market experts give HEB an Outperform rating. Its stock price has been found in the range of 0.13 to 0.35. This is compared to its latest closing price of $0.15.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Hemispherx Biopharma, Inc. [HEB] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 2.00.

Stay on the lookout for the next quarterly financial report – the company is expected to release the following results on Today    ).

Fundamental Analysis of Hemispherx Biopharma, Inc. [HEB]

Now let’s turn to look at profitability: with a current Operating Margin for Hemispherx Biopharma, Inc. [HEB] sitting at -3121.25 and its Gross Margin at -266.08.

This company’s Return on Total Capital is -105.88, and its Return on Invested Capital has reached -99.30%. Its Return on Equity is -141.43, and its Return on Assets is -28.72. These metrics suggest that this Hemispherx Biopharma, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Hemispherx Biopharma, Inc. [HEB] has generated a Total Debt to Total Equity ratio of 114.51. Similarly, its Total Debt to Total Capital is 53.38, while its Total Debt to Total Assets stands at 10.95. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 44.80, and its Long-Term Debt to Total Capital is 20.88. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -1.42. The Enterprise Value to Sales for this firm is now 40.78, and its Total Debt to Enterprise Value stands at 0.49. Hemispherx Biopharma, Inc. [HEB] has a Price to Book Ratio of 1.70.

Shifting the focus to workforce efficiency, Hemispherx Biopharma, Inc. [HEB] earns $11,121 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 0.66 and its Total Asset Turnover is 0.01. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 0.72 and its Current Ratio is 0.72. This company is not investing its short-term assets in an optimally efficient way, making it a riskier investment.

Hemispherx Biopharma, Inc. [HEB] has 72.00M shares outstanding, amounting to a total market cap of $10.71M. Its stock price has been found in the range of 0.13 to 0.35. At its current price, it has moved by -56.55% from its 52-week high, and it has moved 16.09% from its 52-week low.

This stock’s Beta value is currently 0.53, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 45.07. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Hemispherx Biopharma, Inc. [HEB] a Reliable Buy?

Hemispherx Biopharma, Inc. [HEB] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.